ERBB2 and gastric cancer: Among other antiHER2 agents under development, margetuximab, an Fc-modified chimeric monoclonal antibody, has shown promising results in early-phase clinical studies for HER2-expressing solid tumors, including low HER2-expressing gastric cancer [32].